Floatz Rating
CCC55/100
Confidence
Indicative
Sponsor
Rana McKay, MD
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05498272CT.gov Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations | — | Recruiting | — | — | — |
NCT04951492CT.gov Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | — | Terminated | — | — | — |
NCT04336943CT.gov Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load | — | Terminated | — | — | — |
NCT03317392CT.gov Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis | — | Active Not Recruiting | — | — | — |
NCT03570476CT.gov Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | — | Terminated | — | — | — |
NCT03516812CT.gov Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03432897CT.gov BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes | — | Terminated | — | — | — |
NCT02893917CT.gov Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT01682772CT.gov TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olaparib (this asset) | Rana McKay, MD | P2 | CCC · 55 |
| Docetaxel | Instituto do Cancer do Estado de São Paulo | P3 | BBB |
| Prednisone | Mayo Clinic | P3 | BB |
| Nilutamide | SWOG Cancer Research Network | P3 | BB |
| Degarelix | Canadian Cancer Trials Group | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P2 | BB |
| Bicalutamide | OHSU Knight Cancer Institute | P3 | BB |
| Goserelin | CancerCare Manitoba | P3 | BB |
| Leuporelin | Mayo Clinic | P3 | BB |
+42 more in the Prostate Adenocarcinoma cohort
Other indications for Olaparib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Carcinoma | — | P4 | BBB · 73 |
| Fallopian Tube Serous Adenocarcinoma | — | P3 | BBB · 72 |
| Ovarian Carcinoma | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Olaparib in Prostate Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/olaparib-prostate-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →